The U.S. Food and Drug Administration approved Mylan NV's generic version of Pfizer Inc.'s birth control injection Depo-Provera.
Mylan is offering the hormonal contraceptive medroxyprogesterone acetate in single-dose vials.
Sales of the drug in the U.S. were about $181 million for the year ending July 31, the company said in an Oct. 18 news release, citing IQVIA data.
Mylan develops and markets generic, brand-name and over-the-counter products worldwide.